Content area
Full Text
Description
A 64-year-old gentleman was diagnosed with acute myeloid leukaemia (AML) 3 years ago and was treated with cytarabine and daunorubicin induction chemotherapy followed by three cycles of high-dose cytarabine consolidation treatment. Patient tolerated treatment extremely well and went into remission. About 4 months ago, he developed relapse of AML. He was admitted to our inpatient oncology service to begin high-dose cytosine arabinoside chemotherapy in anticipation of allogenic bone marrow transplant. 1
On day 3 of chemotherapy, patient started developing...